Key facts
- This page summarizes GNI Group Ltd.'s Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Oct 2023, 21:56.
GNI Group Ltd. - 27 Oct 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- GYRE
- Reported as of
- 27 Oct 2023
- Net transaction value
- +$4,999,852
- SEC form
- 4
- Accepted by SEC
- 31 Oct 2023, 21:56:40 UTC
- Prior SEC filing
- 01 Sep 2023
- Next SEC filing
- 22 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GNI Group Ltd. filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 31 Oct 2023.
Change
- Previous filing in this sequence was filed on 01 Sep 2023.
- Current net transaction value: +$4,999,852.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CBIO
transaction
Derivative
Series X Convertible Preferred Stock
Purchase
- Transaction value
- $3,986,065
- Shares
- +811
- Change %
- +6.6%
- Price
- $4915.00*
- Shares after
- 13,151
- Date
- 27 Oct 2023
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 811,000
- Exercise price
- Footnotes
- F1, F2, F3
CBIO
transaction
Derivative
Series X Convertible Preferred Stock Warrant (Right to Buy)
Purchase
- Transaction value
- $1,013,788
- Shares
- +8,110,300
- Change %
- Price
- $0.1250
- Shares after
- 8,110,300
- Date
- 27 Oct 2023
- Ownership
- See Footnote
- Underlying class
- Series X Convertible Preferred Stock
- Underlying amount
- 811
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).
Footnote F2
The Preferred Stock has no expiration date.
Footnote F3
These securities are held by GNI USA, Inc., a Delaware corporation ("GNI USA") which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.
Footnote F4
These warrants have an exercise price of $4,915.00 per share of Preferred Stock.